News
MRNA
36.94
-0.94%
-0.35
QQQ ETF Update, 11/21/2024 
TipRanks · 2h ago
CDC warns against a spike in COVID, flu cases
Seeking Alpha · 17h ago
U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks
Benzinga · 19h ago
Is Investing in Moderna Stock (NASDAQ:MRNA) Simply Dead Money?
TipRanks · 19h ago
Franklin Biotechnology Discovery Fund Q3 2024 Commentary
Seeking Alpha · 21h ago
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Benzinga · 23h ago
VOO ETF Update, 11/20/2024 
NASDAQ · 1d ago
Tuesday Sector Laggards: Energy, Healthcare
NASDAQ · 1d ago
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Seeking Alpha · 1d ago
BioNTech started at buy, Moderna at hold by Berenberg
Seeking Alpha · 1d ago
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
Barron‘s · 1d ago
Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
SPY ETF Update, 11/19/2024 
TipRanks · 2d ago
Moderna initiated with a Hold at Berenberg
TipRanks · 2d ago
Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX)
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP-Equifax, Microstrategy, Netflix
Reuters · 2d ago
Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
TipRanks · 2d ago
MODERNA <MRNA.O>: BERENBERG INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $42
Reuters · 2d ago
*Moderna Started at Hold by Berenberg
Dow Jones · 2d ago
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Benzinga · 2d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.